Alix Alderman

Vice President of Regulatory Affairs at PellePharm, Inc.

Alix Alderman

Alix Alderman

Vice President of Regulatory Affairs at PellePharm, Inc.

Overview
RelSci Relationships

109

Contact Data
Trying to get in touch with Alix Alderman? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Alix Alderman likely has professional access to. A relationship does not necessarily indicate a personal connection.

Senior Vice President & Head of Operations at PellePharm, Inc.

Relationship likelihood: Average

President, Chief Executive Officer & Director at PellePharm, Inc.

Relationship likelihood: Average

Co-Founder at PellePharm, Inc.

Relationship likelihood: Average

Co-Founder & Director at PellePharm, Inc.

Relationship likelihood: Average

Co-Founder at Fate Therapeutics, Inc.

Relationship likelihood: Average

Treasurer & Director at MyoTherix, Inc.

Relationship likelihood: Average

Chief Human Capital Officer at MyClean, Inc.

Relationship likelihood: Weak

Senior Vice President of Global Regulatory Affairs at Ultragenyx Pharmaceutical, Inc.

Relationship likelihood: Weak

Senior Corporate Counsel at Ultragenyx Pharmaceutical, Inc.

Relationship likelihood: Weak

Associate Director at Ultragenyx Pharmaceutical, Inc.

Relationship likelihood: Weak

Paths to Alix Alderman
Potential Connections via
Relationship Science
You
Alix Alderman
Vice President of Regulatory Affairs at PellePharm, Inc.
Career History
Vice President of Regulatory Affairs
2018 - Current

PellePharm, Inc. engages in the operation of a biotechnology company committed to targeting rare dermatologic diseases. It develops Patidegib , an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. The firm also focuses on commercializing Patidegib treatment by potentially reducing invasive and painful surgeries. The company was founded by Michael Henderson, Jean Tang, Ervin Epstein, and Philip Beachy and is headquartered in San Francisco, CA.

Senior Director
Prior

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

Other Affiliations

Alix Alderman is affiliated with PellePharm, Inc., Ultragenyx Pharmaceutical, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Alix Alderman. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Alix Alderman's profile does not indicate a business or promotional relationship of any kind between RelSci and Alix Alderman.